disorders of hemostasis. Seventy-three percent of catheters were placed in patients with platelet counts less than 100,000/mL and 40% of catheters were placed in patients with abnormalities of PT, aPTT, or both. Thirteen percent of patients had abnormalities of both platelets and coagulation profile. There were no serious complications. Bleeding complicated 7 (6.5% of the procedures; 5 patients had bleeding from the skin (from the suture sites in four), and 2 patients developed small periosteal hematomas. All patients with bleeding complications had thrombocytopenia with mean platelet counts of 22,000/mL and a range of 6,000 to 37,000/mL. Most patients with platelet counts in this range did not have clinically evident bleeding. Conclusions: Central venous access procedures can be done safely in patients with disorders of hemostasis by skilled physicians who frequently perform these procedures. Patients most likely to experience bleeding from these procedures are patients with severe thrombocytopenia. In this series, only a single patient, with a platelet count of 6,000/mL, required therapeutic blood product administration. (CHEST 1996; 110:185-88) 
is often impractical or impossible to administer blood products prior to obtaining central access.
Our service has placed central venous catheters in patients at a university teaching hospital on a consultation basis for several years. We began doing these procedures in patients with disorders ofhemostasis out of necessity. Having experienced no clinically significant complications in these patients, we have altered our criteria for routine central venous catheter placement in patients with bleeding disorders and we do not routinely administer prophylactic blood products.
We now report our experience with central venous access procedures in patients with disorders of hemostasis over a 12-month period.
MATERIALS AND METHODS
The protocol was approved by the institutional review The medical problems of our patients were varied and are shown in Table 4 . The patients with congestive heart failure were all receiving warfarin, two of the patients with stroke had anticoagulation, one while receiving warfarin and one while receiving heparin. PTs in the patients receiving warfarin ranged from 15.9 to 18 with a mean of 16.3. The category "other diagnoses" includes the following: hemolytic anemia, colitis, connective tissue disease, endocarditis, mixed cryoglobulinemia, hemoptysis, osteomyelitis, dehydration, pancreatitis, amniotic fluid embolism, and myasthenia gravis. Some patients had 2 diagnoses making the total diagnoses greater than 100% and the sum of catheters and patients greater than the totals for the entire population.
None of these patients developed pneumothorax or other evidence of inadvertent lung puncture. No patient had evidence ofintrathoracic bleeding on chest radiograph (defined as new or enlarging fluid collections or enlargement of the mediastinum). No patient experienced an unexplained drop in hematocrit (CBC counts were done as clinically indicated and not specifically for this study). Bleeding at the catheter site complicated 7 catheter placements (6.5%). All seven patients had isolated thrombocytopenia. Five of these patients had bleeding from the skin, related to sutures in four, and the catheter entrance site in one. Two patients developed what clinically were believed to be small (2 to 3 cm diameter) periosteal hematomas ofthe clavicle. One patient with Kaposi's sarcoma of the skin and a platelet count of 6,000/mL received transfusion of 5 U of donor platelets and required 1 h of direct pressure to stop the bleeding from the skin. For the rest, bleeding stopped with direct pressure for 10 to 20 min. The mean platelet count of the patients with bleeding was 22,000/mL; the median was 21,000/mL with a range of 6,000 to 37,000/mL. All of the catheters were in the subclavian position. Six of the seven were placed on a single pass of the needle; the other required four passes for successful cannulation.
Variables that might significantly contribute to the development of hemorrhagic complications were ex- Access to the central venous circulation is often necessary or desirable in the treatment of hospitalized patients. With bleeding as a potential complication, these procedures are often believed to be contraindicated in patients with disorders of hemostasis unless central access can be achieved via a peripheral vein such as the external jugular or antecubital veins. This approach is usually quite limited.
Correction of the coagulopathy by infusion of blood products is often attempted prior to central venous cannulation to minimize the bleeding risk. This practice carries risk of fluid overload and the transmission of blood-borne infections such as hepatitis and HIV as well as economic expense. Additionally, to our knowledge, there are no published data confirming the benefits of this practice in minimizing bleeding complications.
In our practice, central venous catheters are frequently placed in patients with disorders of hemostasis. This is usually done without the prophylactic administration of blood products. Bleeding problems are uncommon and serious bleeding is rare. Only one patient in this series required more than local pressure for more than 20 min. That patient had a platelet count of 6,000/mL and diffuse Kaposi's sarcoma of the skin. This patient and another with acute leukemia received platelets after the procedure. The first was to stop bleeding from the suture site with platelet count of 5,000/mL and the second was at the request of the primary attending physician for platelet count of 15,000/mL. In all three cases, the newly obtained central access was the only route for platelet administration.
Our experience confirms and extends the observations of three other recent studies.4-6 The first4 describes the safe placement ofinternal jugular catheters in patients undergoing transvenous liver biopsies. The second5 involves internal jugular catheter placement in anticoagulated patients undergoing cardiac surgery. The third6 describes placement of both jugular and subclavian catheters in patients undergoing liver transplantation. All report a very low risk of bleeding complications (1%, 5.4%, and 0%). By the definitions used in two studies,4'6 the risk of bleeding in our series was zero. The analysis used in the other study5 was hematoma formation and the result was not different from control and none were clinically significant.
By this report we extend the observations of these previous studies to a much broader patient population. Most of our patients are from the general medical service or ICUs. They are likely to represent the types of patients requiring these procedures in many hospitals. In particular, our patients had frequent thrombocytopenia with a high percentage ofpatients with HIV and/or malignancies. The specific hemostatic disorders are not published in the other three studies. It is likely, by the populations described, that coagulopathies predominated. In our analysis, the platelet count was the only risk factor statistically associated with even minor bleeding (that requiring direct pressure to stop). The platelet count associated with this risk in our series was less than 38,000/mL (in all but one case the number was .25,000/mL). Importantly, even patients receiving warfarin did not have bleeding problems, although the PTs were in the lower end of the therapeutic range.
The risk of serious bleeding complications also appears to be independent of the approach used. Most of the catheters in our patients are placed in the subelavian position, which we frequently prefer as it is generally more comfortable for the patient and easier to keep clean. 7 In all three reports, the operators were experienced in the techniques of central venous cannulation. In ours, an experienced critical care attending physician was involved at all times. Housestaff in training placed many of these catheters with the attending physician present to assist if warranted.
We conclude that central venous cannulation can be safely performed by experienced physicians in patients with disorders of hemostasis. We do not believe that the routine administration of blood products to correct hemostatic abnormalities is warranted under these conditions. Platelets should be available for patients with very low platelet counts in case bleeding is a problem.
